CHANGES IN BLOOD GLUCOSE LEVEL, GLYCOCYLATED HEMOGLOBIN LEVEL AND LIPID PROFILE AS A RESULT OF MONO-HYPOGLYCEMIC THERAPY (METFORMIN) IN TYPE II DIABETES MELLITUS

Abstract

The purpose of the present study is to work out the effect of Metformin as a monotherapy to achieve desired glycemic effect in our society by assessing the levels of fasting blood glucose, lipid profile and HbAIc in Type 2 diabetes mellitus patients. The subjects included in this study were 48 male diabetic patients and 24 male control subjects aged between 26-65 years. Blood samples were taken from the patients and control subjects on two occasions before and after an interval of four months. The Hyperglycemic patients were given Metformin for at least four months after first collection of blood samples. Although no direct relation of better HbAIc level with comparatively better lipid profile has not been possible to established in our selected patients, who were well controlled diabetics, but it can be well apprehended that a better picture of cholesterolemia is seen in diabetic patients with comparatively lower HbA1c level. As a hypoglycemic therapeutic agent, Metformin has a good and reasonable effect on blood glucose level.